Articles by Tomohiko Murase in JoVE
Ovarian Tissue Culture to Visualize Phenomena in Mouse Ovary Kouji Komatsu1, Akira Iwase2,3, Tomohiko Murase2, Satoru Masubuchi1 1Department of Physiology, Aichi Medical University, 2Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 3Department of Maternal and Perinatal Medicine, Nagoya University Hospital Ovarian tissue cultures can be used as models of follicle development, ovulation, and follicle atresia and indicate regulatory mechanisms of dynamic ovarian processes.
Other articles by Tomohiko Murase on PubMed
Involvement of Mesosalpinx in Endometrioma is a Possible Risk Factor for Decrease of Ovarian Reserve After Cystectomy: a Retrospective Cohort Study Reproductive Biology and Endocrinology : RB&E. Oct, 2016 | Pubmed ID: 27793163 Serum anti-Müllerian hormone (AMH) concentration has been used to assess ovarian reserve in patients with endometriosis, especially when endometrioma surgery is involved. Previously, we reported that decreased serum AMH levels after cystectomy for endometriomas can recover to preoperative levels in some cases. In this present study, we assessed the sequential changes in serum AMH levels before and after cystectomy in terms of the state of the mesosalpinx prior to surgery.
Follicle Dynamics: Visualization and Analysis of Follicle Growth and Maturation Using Murine Ovarian Tissue Culture Journal of Assisted Reproduction and Genetics. Feb, 2018 | Pubmed ID: 29080194 To visualize and analyze follicle development in ovarian tissue culture using physiological concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in order to establish an ovarian tissue culture system that enables efficient in vitro growth of follicles.
Clinical Application of Serum Anti-Müllerian Hormone As an Ovarian Reserve Marker: A Review of Recent Studies The Journal of Obstetrics and Gynaecology Research. Mar, 2018 | Pubmed ID: 29517134 It has been more than 15 years since the measurement of serum anti-Müllerian hormone (AMH) first allowed the quantitative assessment of ovarian reserve. Meanwhile, the clinical implication of serum AMH has been expanding. The measurement of serum AMH has been applied in various clinical fields, including assisted reproduction, menopause, reproductive disorders and assessment of ovarian damage/toxicity. Well-known findings about the usefulness of serum AMH revealed by numerous studies executed in the early era include decline with aging, a good correlation with oocyte yield in assisted reproduction, upregulation in polycystic ovarian syndrome and a decrease on ovarian surgery and toxic treatment. More intensive research, including a meta-analysis, cutting-edge clinical trial and advances in AMH assays, has yielded newer findings and firmer clinical interpretations in serum AMH in the past few years. Variations in the AMH decline trajectory in the general population do not support the accurate prediction of menopause. The ability to predict pregnancy in infertility treatment and natural conception is poor, while a nomogram integrating serum AMH as a stimulation protocol is useful for avoiding poor and/or hyper-responses. On the other hand, improvements in measuring very low concentrations of serum AMH may be capable of distinguishing women with poor ovarian function. Age-independent standardization of AMH values may be helpful for comparing ovarian reserves among women at different ages.